4Suppliers
0Customers
3Debt Items
0Related Chains

Reviva Pharmaceuticals Holdings, Inc. Suppliers

TickerNameConfidenceEvidence
API-CONTRACT-MANUFACTURER API-CONTRACT-MANUFACTURER 92% We have an API contract manufacturer to produce bulk batches under GMP for our anticipated clinical studies
CONTRACT-RESEARCH-ORGANIZATIONS CONTRACT-RESEARCH-ORGANIZATIONS 92% The Company determines the amounts to accrue by obtaining reports from its vendors, including the Company's contract research organizations ("CROs"),
CROS CROS 92% The Company determines the amounts to accrue by obtaining reports from its vendors, including the Company's contract research organizations ("CROs"),
VENDOR VENDOR 90% during the nine months ended September 30, 2024 costs from two vendors each represented 37 % and 17 % of total research and development expenses, respectively

Reviva Pharmaceuticals Holdings, Inc. Customers

No clients on recordNo downstream customers found in our database for Reviva Pharmaceuticals Holdings, Inc..

Reviva Pharmaceuticals Holdings, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
RVPH-DEBT-12306 Xbrl Convertible 90% xbrl convertible detail from xbrl 2021-12-31.
RVPH-DEBT-12305 Warrants outstanding: 19075842 90% xbrl warrant detail from xbrl 2026-03-31.
RVPH-DEBT Debt stack $231,274 90% Market cache reports total debt of $231,274.

Reviva Pharmaceuticals Holdings, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Reviva Pharmaceuticals Holdings, Inc..

Reviva Pharmaceuticals Holdings, Inc. Ownership

HolderNameConfidenceEvidence
RVPH-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 5 tracked holders.

Reviva Pharmaceuticals Holdings, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.